(SLTD) Provides Financial and Business Development Update

Balance Sheet Improvements Coupled With New Revenue Streams Strengthen Financial Outlook

(AXN) Has Regained NYSE Compliance with Continued Listing Requirements

JERSEY CITY, NJ / April 23, 2015 / Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) (“Aoxing Pharma”), a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals, has received notice from NYSE MKT that Aoxing Pharma is deemed by NYSE MKT to have regained compliance with the NYSE MKT’s continued listing standards, subject to final review and confirmation of Aoxing Pharma’s representations.

During 2013 and subsequently, NYSE MKT informed Aoxing Pharma that it was out of compliance with the following sections of the NYSE MKT Company Guide:

– Section 1003(a)(i) since it reported stockholders’ equity of less than $2,000,000 at September 30, 2014 and has incurred losses from continuing operations and/or net losses in two of its three most recent fiscal years;

– Section 1003(a)(ii) since it reported stockholders’ equity of less than $4,000,000 at December 31, 2014 and has incurred losses from continuing operations and/or net losses in three of its four most recent fiscal years; and

– Section 1003(a)(iii) since it reported stockholders’ equity of less than $6,000,000 at December 31, 2014 and has incurred losses from continuing operations and/or net losses in its five most recent fiscal years.

Based on the plans of compliance submitted by the Company, the Exchange granted the Company until April 27, 2015 to regain compliance with Sections 1003(a)(i), 1003(a)(ii) and 1003(a)(iii).

This month, Aoxing Pharma notified the NYSE MKT that, based on Aoxing Pharma’s preliminary balance sheet as of March 31, 2015, Aoxing Pharma believes that, after giving effect to the sale on April 8, 2015 to investors and a creditor of 1,029,412 common shares for $1,400,000, the Company’s stockholders equity balance after completion of these transactions is approximately $6.7 million, which exceeds NYSE MKT continued listing requirements. Accordingly, the NYSE MKT has deemed Aoxing Pharma back in compliance with its continued listing requirements, subject to final review and confirmation of the information to be reported in the Company’s Form 10-Q, which is expected to be filed with the SEC on or about May 15, 2015.

About Aoxing Pharmaceutical Company, Inc.

Aoxing Pharmaceutical Company, Inc. is a US incorporated specialty pharmaceutical company with its operations in China, specializing in research, development, manufacturing and distribution of a variety of narcotics and pain-management products. Headquartered in Shijiazhuang City, outside Beijing, Aoxing Pharma has the largest and most advanced manufacturing facility in China for highly regulated narcotic medicines. Its facility is one of the few GMP facilities licensed for the manufacture of narcotic medicines by the China State Food and Drug Administration (SFDA). For more information, please visit: www.aoxingpharma.com.

CONTACT:

Aoxing Pharmaceutical Company:
646-367-1747
investor.relations@aoxingpharma.com

(MDSO) Rouven Bergmann, CFO SAP North America to Join as Chief Financial Officer

Medidata (NASDAQ:MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced that Rouven Bergmann is joining the company as Chief Financial Officer effective Monday, May 18, 2015. Bergmann’s financial and operational experience managing a multibillion-dollar software business extends the breadth and depth of Medidata’s leadership team. Medidata also reaffirmed today that there is no change to its 2015 financial guidance.

“We are excited to have Rouven’s proven financial leadership on the Medidata team, as we continue to scale our business and execute our growth strategy,” said Medidata’s chairman and chief executive officer Tarek Sherif. “His experience makes him ideally suited to assume the role of Medidata’s CFO as we capitalize on new opportunities for innovation in our rapidly evolving market. Importantly, he is also a strong cultural fit for our Company.”

As Chief Financial Officer of SAP North America, Bergmann was responsible for overseeing all financial activities for SAP’s largest business unit. His key accomplishments include driving SAP’s transition from a traditional licensing model to SaaS (software-as-a-service) and leading transformational acquisition integrations. Since joining SAP in 2005, Bergmann has served as chief operating officer for SAP’s global R&D organization, as well as in key leadership roles in Waldorf, Germany; Bangalore, India; and Palo Alto. He earned masters degrees in mechanical engineering and business administration from Technical University of Kaiserslautern in Germany and a PhD in economics and finance from the University of Munich in Germany.

“Medidata is at a transformational stage in its development and is well-positioned to deliver long-term value to both clients and shareholders,” said Bergmann. “I’m excited about the opportunity to drive Medidata’s business forward and help accelerate transformation in the drug development industry through the adoption of Medidata’s innovative cloud-based platform and services.”

Cory Douglas, Medidata’s current Chief Financial Officer, will pursue opportunities outside of Medidata by mutual agreement upon Bergmann’s start. Sherif stated, “Cory has been a key contributor and a great team player during a period of significant change and growth at Medidata. He will be missed and we wish him all the best. We thank Cory for his service to Medidata throughout his tenure.”

About Medidata Solutions

Medidata is the leading global provider of cloud-based solutions for clinical research in life sciences, transforming clinical development through its advanced applications and intelligent data analytics. The Medidata Clinical Cloud^® brings new levels of productivity and quality to the clinical testing of promising medical treatments, from study design and planning through execution, management and reporting. We are committed to advancing the competitive and scientific goals of global customers, which include over 90% of the top 25 global pharmaceutical companies; innovative biotech, diagnostic and device firms; leading academic medical centers; and contract research organizations.

Medidata Solutions
Investor Contact:
Hulus Alpay, 212-419-1025
halpay@mdsol.com
or
Media Contact:
Nicole Pariser, 212-659-1069
npariser@mdsol.com

(LOOK) Announces Spin-Off and Definitive Merger Agreement with Pyxis

SAN FRANCISCO and ATHENS, Greece, April 23, 2015 — LookSmart, Ltd. (NASDAQ: LOOK) and privately-held Pyxis Tankers Inc. (“Pyxis“) today jointly announced that they have entered into an Agreement and Plan of Merger (the “Merger Agreement“), whereby Pyxis will become a publicly listed company as a result of the merger between LookSmart, Ltd. (“LookSmart“) and Pyxis’ wholly-owned subsidiary, Maritime Technologies Corp., a Delaware corporation. In addition, LookSmart will spin off its existing business into a new entity called LookSmart Group, Inc. (“LookSmart Group“).

Pyxis Tankers Inc.

Pyxis Tankers Inc. is a newly formed international maritime transportation company with a focus on the tanker sector. At the consummation of the merger with LookSmart, Pyxis’ fleet will be comprised of six double hull product tankers with an average current age of four years and that are employed under a mix of short- and medium-term time charters and spot charters. Pyxis will acquire these six vessels prior to the merger from an affiliate of its founder and chief executive officer, Mr. Valentios (“Eddie”) Valentis. Four of the vessels in the fleet will be medium-range, or MR, product tankers, three of which have eco-efficient or eco-modified designs and two will be short-range tanker sister ships. Each of the vessels in the fleet is capable of transporting refined petroleum products, such as naphtha, gasoline, jet fuel, kerosene, diesel and fuel oil, as well as other liquid bulk items, such as vegetable oils and organic chemicals.

Pyxis’ principal objective will be to own and operate its fleet in a manner that will enable it to benefit from short- and long-term trends that Pyxis expects in the product tanker sector to maximize its revenues and to enhance returns to its stockholders. Pyxis intends to expand the fleet through selective acquisitions of modern product tankers in a manner that is accretive to stockholder value. It expects to employ its vessels primarily through time charters to creditworthy customers and on the spot market. Pyxis intends to continually evaluate the markets in which it operates and, based upon its view of market conditions, adjust its mix of vessel employment by counterparty and stagger its charter expirations. In addition, Pyxis may choose to opportunistically direct asset sales when opportunities exist for subsequent accretive vessel acquisitions and conditions are primed to generate attractive returns for its stockholders.

Mr. Valentis commented, “A publicly-traded growth-oriented product tanker company will be created upon closing of the merger that we believe is unique among our competitors. We at Pyxis Tankers look forward to communicating to the LookSmart shareholders and the investment community about our value creation story and growth opportunities.”

The Transactions

Spin-Off

Prior to the execution of the Merger Agreement, LookSmart transferred all of its businesses, assets and liabilities (including its Clickable, Ad Center and web search businesses) to LookSmart Group. Upon completion of this spin-off, LookSmart Group, will be 100% owned by LookSmart’s stockholders of record.

Merger

Under the terms of the Merger Agreement, LookSmart will merge with and into Maritime Technologies Corp., which will be the surviving corporation in the merger and will continue to be a wholly-owned subsidiary of Pyxis. Upon completion of the merger, each share of LookSmart’s common stock issued and outstanding immediately prior to the merger will be exchanged for the right to receive a certain number of shares of Pyxis’ common stock equal to $4,000,000, as adjusted for the price and number of LookSmart’s outstanding common stock as of the date that the merger becomes effective.  After the completion of the merger, and assuming no adjustments pursuant to the terms of the Merger Agreement, the public stockholders of LookSmart are expected to own approximately 5.66% of the total issued and outstanding common stock of Pyxis.

Pyxis intends to apply to have its common stock listed on either the Nasdaq Capital Market or the NYSE MKT under the symbol “PXS.”

LookSmart’s Chief Executive Officer, Michael Onghai, stated, “We are very pleased to give our stockholders this value enhancing transaction. Our stockholders will have an opportunity to also own shares in Pyxis without diluting their existing ownership in LookSmart and its subsidiaries including Clickable, Inc., all of which will be transferred into a new entity called LookSmart Group, Inc. This transaction enables LookSmart Group to remain public with lower costs of being public and more flexibility for its fast-growing subsidiaries to raise capital with alternative sources of financing such as venture capital. At the same time, this transaction offers Pyxis a chance to be listed on a major stock exchange.”

The Make Whole Record Date

In the event that subsequent to the Merger, Pyxis completes a financing which results in gross proceeds to Pyxis of at least $5,000,000 (a “Future Pyxis Offering”) at a valuation lower than the valuation ascribed to the shares of common stock received by LookSmart stockholders pursuant to the Merger Agreement (the “Consideration Value”), Pyxis will be obligated to make “whole” the LookSmart stockholders as of April 29, 2015 (the “Make Whole Record Date”) by offering such LookSmart stockholders the right to receive additional shares of Pyxis common stock to compensate the LookSmart stockholders for the difference in value of their Pyxis common stock.

In addition, should Pyxis fail to complete a Future Pyxis Offering within a date which is 3 years from the date of the closing of the Merger, each holder of the Company’s common stock who has held such stock continuously from the date of the Make Whole Record Date until the expiration of such 3 year period (the “Legacy LS Stockholders”) will have a 24-hour option beginning at the end of the 3 year period to require Pyxis to purchase from such Legacy LS Stockholders a pro rata amount of Pyxis common stock that would result in aggregate gross proceeds to the Legacy LS Stockholders in an amount not to exceed $2,000,000; provided that in no event shall a Legacy LS Stockholder receive an amount per share greater than the Consideration Value.

About LookSmart, Ltd.

LookSmart is a pioneer in online advertising. Founded in 1997, LookSmart has been connecting advertisers and agencies to high quality sources of inventory for performance marketing, and helps online publishers monetize their inventory through our award winning Ad Center platform. LookSmart’s highly scalable technology processes billions of search queries on a daily basis, enabling marketers to bid in real-time across search and display inventory, and leverage intent data to get performance that meets aggressive campaign goals. LookSmart also operates Clickable.com, a technology-enabled solutions company that uses social media data to help some of the world’s most valuable brands understand their customer needs and improve performance, as well as providing a technology-enabled services company that helps companies and agencies manage their online marketing for themselves and their clients. LookSmart is based in San Francisco, California. For more information, visit www.looksmart.net, www.clickable.com, or call (415) 348-7000.

Additional Information and Where to Find It

In connection with the proposed merger, LookSmart and Pyxis will prepare a proxy statement/prospectus for LookSmart’s stockholders proxy and a registration statement on Form F-4 to be filed with the SEC.  LookSmart’s proxy statement/prospectus will be mailed to LookSmart’s stockholders that do not opt to receive the document electronically.  LookSmart and Pyxis urge investors, stockholders and other interested persons to read, when available, the proxy statement/prospectus, as well as other documents filed with the SEC, because these documents will contain important information.

Such persons can also read LookSmart’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014, for a description of the security holdings of its officers and directors and their respective interests as security holders in the successful consummation of the transactions described herein. LookSmart’s definitive proxy statement/prospectus, which will also be included in Pyxis’ registration statement, will be mailed to stockholders of LookSmart as of a record date to be established for voting on the transactions described in this report. LookSmart’s stockholders will also be able to obtain a copy of such documents, without charge, by directing a request to: LookSmart, Ltd., 50 California Street, 16th Floor, San Francisco, CA 94111.  These documents, once available, can also be obtained, without charge, at the Securities and Exchange Commission’s web site (http://www.sec.gov).

Participants in Solicitation

Maxim Group LLC acted as sole financial advisor to Pyxis in connection with the proposed Merger, for which it will receive a fee. Additionally, Gruppo, Levy & Co. and Source Capital Group, Inc. provided a fairness opinion to the Company in connection with the proposed Merger, for which they will receive a fee. The Company and its directors and executive officers, Maxim Group LLC, Gruppo, Levy & Co. and Source Capital Group, Inc. may be deemed to be participants in the solicitation of proxies for the special meeting of the Company’s stockholders to be held to approve the Transactions described in this report. Information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of the Company’s stockholders in connection with the proposed Transactions will be set forth in the proxy statement/prospectus when it is filed with the SEC. You can find information about the Company’s executive officers and directors in its Annual Report on Form 10-K, which was filed with the SEC on March 17, 2015. You can obtain free copies of these documents from the Company using the contact information above.

Non-Solicitation

This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed transaction and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of LookSmart, LookSmart Group, Pyxis or Maritime Technologies Corp., nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Safe Harbor Language

This press release includes “forward-looking statements” within the meaning of U.S. federal securities laws. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results and, consequently, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements and factors that may cause such differences include, without limitation, LookSmart’s and Pyxis’ expectations with respect to future performance, growth and anticipated acquisitions; the anticipated financial impact of the merger; ability to recognize the anticipated benefits of the merger; costs related to the proposed merger; the satisfaction of the closing conditions to the merger; the timing of the completion of the merger; volatility in charter rates and profitability; demand for shipping of refined petroleum products; global economic conditions; changes in fuel prices; geopolitical events and regulatory changes; damages to vessels; acts of piracy, political instability, terrorist or other attacks, war or international hostilities; loss of key personnel; delays in deliveries of product tankers; difficulty managing planned growth properly; seasonal and exchange rate fluctuations; access to additional financing; changes in tax laws; weather and natural disasters; changing interpretations of generally accepted accounting principles; inquiries and investigations and related litigation; continued compliance with government regulations; and other risks and uncertainties indicated from time to time in filings with the SEC. The foregoing list of factors is not exclusive. Additional information concerning these and other risk factors is contained in LookSmart’s most recent filings with the SEC and will be contained in the proxy statement/prospectus to be filed as result of the transactions described above. All subsequent written and oral forward-looking statements concerning LookSmart, LookSmart Group, Pyxis or Merger Sub, the transactions described herein or other matters and attributable to LookSmart, LookSmart Group, Pyxis or Merger Sub, or any person acting on their behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Neither LookSmart, LookSmart Group, Pyxis nor Merger Sub undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement to reflect any change in their expectations or any change in events, conditions or circumstances on which any such statement is based.

(ANY) and Microsoft to Showcase Virtualization and Cloud Solutions

Joint Roadshow Will be Held at Microsoft Technology Centers and Include Demonstrations of Sphere 3D’s Technologies for the “Next Cloud”

SAN JOSE, Calif., April 23, 2015  — Sphere 3D Corp. (Nasdaq:ANY), a virtualization and data management solutions provider, today announced that in collaboration with Microsoft, the company will showcase its technologies and product solutions during a joint global partner roadshow that will be hosted at multiple Microsoft Technology Center (MTCs) locations. During these events, Sphere 3D will present its cloud-enabling technologies, including Glassware 2.0 Windows container technology for application delivery, and virtualized storage technologies for enterprise hybrid cloud infrastructure, to a combined audience of Microsoft and Sphere 3D channel partners.

Sphere 3D and Microsoft have confirmed the schedule for the events at the Microsoft Technology Center in Silicon Valley/Mt. View, CA on May 20, 2015, and in New York on May 27, 2015. Dates for the events in London and Toronto will be announced shortly. Resellers and channel partners of Sphere 3D and Microsoft can register for these exclusive events at http://sphere3d.com/events/microsoft-azure/index.html.

“We are excited to have the opportunity to showcase our portfolio of cloud enabling solutions to a combined group of Microsoft and Sphere 3D partners,” said Eric Kelly, CEO of Sphere 3D Corp. “The Microsoft Technology Centers are excellent venues for us to show partners how they can leverage our unique technology in combination with Microsoft Azure to simplify and accelerate customers’ transition to cloud-integrated solutions.”

The Microsoft Technology Centers are collaborative environments, currently located in 37 major cities around the world, which provide access to innovative technologies and world-class expertise, enabling customers to envision, design, and deploy solutions to meet their exact needs. The MTCs include a spectrum of purpose-built environments of comprehensive resources, including hardware, software, and services to ensure world-class learning and development experiences.

About Sphere 3D

Sphere 3D Corp. (Nasdaq:ANY) is a virtualization technology and data management solutions provider with a portfolio of workload-optimized solutions that address IT needs for delivering productivity through workspace and data infrastructure and management. Dedicated to continue to lead through innovation, Sphere 3D enables the integration of virtual applications, virtual desktops, and storage into workflow, and allows organizations to deploy a combination of public, private or hybrid cloud strategies. Sphere 3D’s Glassware 2.0® platform delivers virtualization of some of the most demanding applications in the marketplace today, making it easy to move applications from a physical PC or workstation to a virtual environment. Sphere 3D’s V3 hyper-converged infrastructure solutions include one of the industry’s first purpose-built appliances for virtual workspace workloads and the Desktop Cloud Orchestrator™ management software for VDI. Overland Storage and Tandberg Data, wholly-owned subsidiaries of Sphere 3D, provide an integrated range of technologies and services for primary, nearline, offline, and archival data storage that make it easy and cost-effective to manage different tiers of information over the data lifecycle. For more information, visit www.sphere3d.com.

Safe Harbor Statement

This press release contains forward-looking statements that involve risks, uncertainties, and assumptions that are difficult to predict. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties including, without limitation, unforeseen changes in the course of Sphere 3D’s business or the business of its wholly-owned subsidiaries, including, without limitation, Overland Storage and Tandberg Data; any increase in Sphere 3D’s cash needs or our inability to obtain additional debt or equity financing; market adoption and performance of our products; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in Sphere 3D’s periodic reports contained in our Annual Information Form and other filings with Canadian securities regulators (www.sedar.com) and in prior periodic reports filed with the United States Securities and Exchange Commission (www.sec.gov), and risks detailed in the Form F-4/A relating to Sphere 3D’s merger with Overland Storage filed with the SEC. Sphere 3D undertakes no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

CONTACT: Media Contact:
         Pattie Adams
         Director, Global Corporate Communications
         +1 408/283-4779
         pattie.adams@sphere3d.com

(MCHX) Announces Sale of Its Domain Assets

Marchex, Inc. (NASDAQ: MCHX), a mobile advertising analytics company, today announced the sale of the bulk of its domain portfolio for aggregate proceeds of $34.8 million, as well as additional earn-out considerations. The $34.8 million total includes a $28.1 million transaction detailed below, as well as $6.7 million in direct domain sales by Marchex since January 2015.

The company has entered into a definitive agreement to sell more than 200,000 domains to GoDaddy Inc., the world’s largest technology provider dedicated to small businesses. Under the agreement, Marchex received cash consideration of $28.1 million upon closing plus additional earn-out payments subject to certain sales targets.

“Our complete focus is on establishing Marchex as the world’s leading mobile advertising analytics company,” said Pete Christothoulou, Marchex Chief Executive Officer. “A significant and growing majority of the consumer engagement and sales driven by mobile advertising happens offline, such as through phone calls. Narrowing our focus on this opportunity, while growing our balance sheet, strengthens our ability to continue delivering technology solutions that bring accountability to mobile advertising and transform business performance for our clients.”

About Marchex:

Marchex is a mobile advertising analytics company that connects online behavior to real-world, offline actions. By linking critical touchpoints in the customer journey, Marchex’s products enable a 360-degree view of marketing effectiveness. Brands and agencies utilize Marchex’s products to transform business performance.

Please visit www.marchex.com, blog.marchex.com or @marchex on Twitter (Twitter.com/Marchex), where Marchex discloses material information from time to time about the company, its financial information, and its business.

Forward-Looking Statements:

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenues, acquisitions, projected costs, prospects, plans and objectives of management are forward-looking statements. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. There are a number of important factors that could cause Marchex’s actual results to differ materially from those indicated by such forward-looking statements which are described in the “Risk Factors” section of our most recent periodic report and registration statement filed with the SEC. All of the information provided in this release is as of April 22, 2015 and Marchex undertakes no duty to update the information provided herein.

(CAPR) Granted FDA Orphan Drug Designation for Allogeneic Cardiosphere-Derived Cells

LOS ANGELES, April 22, 2015  — Capricor Therapeutics, Inc. (Nasdaq:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that it has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for its cell therapeutic product candidate, CAP-1002, for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD).

Cardiosphere-derived cells (CDCs), also known as CAP-1002, are a potential therapeutic approach for the treatment of Duchenne muscular dystrophy-associated cardiomyopathy. The cells have been shown to promote cardiomyogenesis and angiogenesis, while inhibiting oxidative stress, inflammation and fibrosis in preclinical studies. Pre-clinical data presented at the American Heart Association’s annual meeting in November 2014 demonstrated that cardiac function and exercise capacity improved in CDC-treated mdx mice, accompanied by attenuation of inflammation, improved mitochondrial function and a reduction in collagen content and fibrosis in CDC-treated mdx hearts. The findings raise the possibility that CDCs may be useful therapeutically for heart failure in patients with Duchenne muscular dystrophy.

“We are pleased to have received orphan drug designation for CAP-1002 for the treatment of DMD,” said Linda Marbán, Ph.D., Chief Executive Officer of Capricor. “Duchenne cardiomyopathy is a devastating complication of the disease that impacts virtually all those affected by the disease and is the leading cause of death in patients. We believe CDCs are uniquely suited to treat the cardiac component of DMD and could potentially be used in conjunction with any of the therapeutics currently in use or under investigation for the skeletal muscle pathology. Capricor is addressing the devastating cardiac complications for which there is no specific treatment. We anticipate filing an IND with the FDA in the near future and hope to be treating patients with Duchenne later this year subject to regulatory approval. We look forward to reporting additional milestones as they are achieved.”

About Orphan Drug Designation

Orphan Drug Designation is granted by the FDA Office of Orphan Drug Products to drugs intended to treat a rare disease or condition affecting fewer than 200,000 people in the U.S. This designation confers special incentives to the drug developer, including tax credits on the clinical development costs, prescription drug user fee waivers and may allow for a seven year period of market exclusivity in the U.S. upon FDA approval.

About Capricor Therapeutics

Capricor Therapeutics, Inc. (Nasdaq:CAPR) is a clinical-stage biotechnology company with expertise in the field of cardiovascular disease aiming to develop novel therapies for diseases with tremendous unmet medical needs. Our lead programs target post myocardial infarction (heart attack), heart failure and Duchenne Muscular Dystrophy. The Company has two leading product candidates under investigation: Cenderitide, a natriuretic peptide receptor agonist, and CAP-1002, a cardiac cell therapy. Cenderitide is in development for the outpatient treatment of heart failure as well as potential other indications. CAP-1002 is in development for the treatment of post myocardial infarction (heart attack), advanced heart failure and Duchenne muscular dystrophy cardiomyopathy. In addition, the Company is conducting research and development on its exosomes platform technology for cardiac diseases and other potential indications. For additional information visit www.capricor.com.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor’s product candidates; the conduct, size, timing and results of discovery efforts and clinical trials; scope, duration, validity and enforceability of intellectual property rights; plans regarding regulatory filings, future research and clinical trials; plans regarding current and future collaborative activities and the ownership of commercial rights; future royalty streams, and any other statements about Capricor’s management team’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “should,” “target,” “will,” “would” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact our business are set forth in our Annual Report on Form 10-K for the year ended December 31, 2014, as filed with the Securities and Exchange Commission on March 16, 2015, and in our Registration Statement on Form S-1, as filed with the Securities and Exchange Commission on March 6, 2015. All forward-looking statements in this press release are based on information available to us as of the date hereof, and we assume no obligation to update these forward-looking statements.

CONTACT: For more information, please contact:

         Corporate Contact
         Capricor Therapeutics, Inc.
         AJ Bergmann, Vice President of Finance 
         +1-310-358-3200
         abergmann@capricor.com  

         Media Relations
         Russo Partners
         Christopher Hippolyte
         +1-646-942-5634
         chris.hippolyte@russopartnersllc.com 

         Tony Russo, Ph.D.
         +1-212-845-4251
         tony.russo@russopartnersllc.com

         Investor Relations:
         Russo Partners 
         Robert Flamm, Ph.D.
         +1-212-845-4226
         robert.flamm@russopartnersllc.com

(CRBP) Receives $5 Million Development Award From Cystic Fibrosis Foundation

Award Supports Initiation of Phase 2 Clinical Trial With Resunab, a Novel Oral Anti-Inflammatory and Anti-Fibrotic Drug, in Individuals With Cystic Fibrosis; Study Expected to Begin This Quarter; Corbus Management Team to Host Conference Call and Webcast at 10 a.m. EDT Today

(ARRS) to Acquire Pace plc for $2.1 Billion in Stock and Cash

Acquisition is expected to generate significant earnings accretion for ARRIS

SUWANEE, Ga. and SALTAIRE, UK, April 22, 2015  — ARRIS Group, Inc. (NASDAQ: ARRS), a global innovator in broadband media technology, and Pace plc. (LSE: PIC) today jointly announced that they have agreed that ARRIS will acquire Pace for aggregate stock and cash consideration of US$2.1 billion (£1.4 billion). The acquisition is expected to be accretive to ARRIS Non-GAAP earnings per share in the first 12 months following the acquisition.

Key benefits of the transaction:

• Accelerates growth strategy
  • ~US$8B Pro forma revenues
  • ~8,500 combined employees, globally based
  • Provides large scale entry into satellite segment
  • Enhances international presence
  • Expands product portfolio across equipment, software, and services
• Financially compelling
  • US$0.45 to US$0.55 accretive in the first 12 months after close to Non-GAAP EPS
  • Reduces Non-GAAP tax rate to approximately 26% – 28%
  • Significant synergy opportunity
  • Maintains capital structure flexibility

Transaction details:
The transaction will result in the formation of New ARRIS, which will be incorporated in the U.K., and its operational and worldwide headquarters will be in Suwanee, GA USA. New ARRIS is expected to be listed on the NASDAQ stock exchange under the ticker ARRS. In connection with the formation of New ARRIS each current share of ARRIS will be exchanged for one share in New ARRIS.

Under the agreed upon terms, Pace shareholders will receive £1.325 of cash and a fixed exchange ratio of 0.1455 New ARRIS shares for each Pace share, reflecting aggregate consideration as of April 21, 2015 of £4.265 per share, representing a 28% premium to the Pace closing share price as of April 21, 2015. The cash portion will be funded through a combination of cash and debt.  ARRIS has secured a fully committed facility from Bank of America Merrill Lynch to meet the funding requirements.

Pace shareholders will receive approximately 48.2 million shares of New ARRIS in aggregate. On a pro forma basis current ARRIS shareholders will hold ~76% of New ARRIS and Pace shareholders will hold ~24% of New ARRIS. The transaction is expected to be taxable, for U.S. federal income tax purposes, to the shareholders of ARRIS.

The proposed transaction has been approved by the respective Boards of Directors of ARRIS and Pace and is expected to close in late 2015 after the satisfaction of customary closing conditions, including ARRIS and Pace shareholder approval and regulatory approvals.

ARRIS Chairman and CEO, Bob Stanzione will be New ARRIS Chairman and CEO and the then-current ARRIS Board of Directors will serve as the New ARRIS Board of Directors.

“This transaction is another example of ARRIS’s ongoing strategy of investing in the right opportunities to position our company for growth. Adding Pace’s talent, products and diverse customer base will provide ARRIS with a large scale entry into the satellite segment, broaden our portfolio and expand our global presence. We expect this merger will enable ARRIS to increase its speed of innovation. We believe this is a tremendous opportunity for ARRIS and our customers, employees, shareholders and partners around the world as we collaborate to invent the future,” said Bob Stanzione. “We look forward to working with the talented and accomplished team at Pace.”

“Pace plc is a great company with a strong track record of pioneering innovation and excellent customer service. Through a combination of organic development and acquisitions, Pace has grown to be a leading technology solutions provider to the PayTV and Broadband industries serving cable, satellite and telco customers across the globe. Over the last three years, Mike Pulli and the wider Pace team have successfully executed against our strategic plan to develop Pace into a more distinctive, profitable and cash generative company, creating significant value for shareholders.

“The Pace Directors believe that ARRIS’s offer recognises this value and also gives our shareholders the opportunity to share in the future success of the combined group. While we believe that Pace is strongly positioned to continue to execute its strategy in the medium and long term, we believe that the combination of the complementary ARRIS and Pace businesses will create a platform for future growth above and beyond our standalone potential. We believe this is a great fit for both companies, our employees, customers and trading partners,” said Allan Leighton, Chairman of Pace.

Evercore is acting as lead financial advisor; Troutman Sanders is acting as lead US legal counsel and Herbert Smith Freehills is acting as lead UK legal counsel to ARRIS on this transaction. Bank of America Merrill Lynch is also advising ARRIS. J.P. Morgan Cazenove is acting as lead financial advisor and Travers Smith is acting as lead legal counsel to Pace on this transaction.

Conference Call and Webcast Details
ARRIS will host a conference call at 5:00 pm ET today to discuss this announcement. You may participate in this conference call by dialing (888) 713-4218 or (617) 213-4870 from the US, 080 0055 6013 or +44 20 7136 5118 from the UK prior to the start of the call and providing the ARRIS Group, Inc. name, conference pass code 14190410, and Bob Puccini as the moderator. A replay of the conference call can be accessed approximately two hours after the call through April 29, 2015 by dialing (888) 286-8010 or (617) 801-6888 and using the pass code 55255256. Live internet access to the call will be available through the Investor Relations section of the Company’s website at www.arris.com. A replay will also be made available for a period of 12 months following the conference call on ARRIS’s website at www.arris.com.

Pace acquisition-specific documents can be found at www.arris.com/pace

About ARRIS:
ARRIS is a global innovator in IP, video and broadband technology. We have continually worked with our customers to transform the experience of entertainment and communications for millions of people around the world. The people of ARRIS are dedicated to the success of our customers, bringing a passion for invention that has fueled our history: we created digital TV, delivered the first wireless broadband gateway and are pioneering the standards and pathways for tomorrow’s personalized, Ultra HD, multiscreen, and cloud services. We are dedicated to meeting today’s challenges and preparing for the tasks the future holds. Collaborating with our customers, ARRIS will continue to solve the most pressing challenges of 21st century communications. Together, we are inventing the future. For more information: www.arris.com

For the latest ARRIS news:
Check out our Blog: ARRIS EVERYWHERE
Follow us on Twitter @ARRIS EVERYWHERE

About Pace:
Pace (LSE: PIC) is a leading provider of technology solutions to the PayTV and Broadband industries. With a broad portfolio of customer premises equipment, network solutions, and software and services, Pace empowers service providers to simply and cost-effectively innovate at the speed they want, and to define the evolution of their networks in the way they want for their subscribers. Pace has built up its experience and expertise over 30 years and this is recognized by a customer base of over 200 operators around the globe.

Headquartered in the UK, Pace operates in markets across the world, and employs around 2,300 people in locations that also include the USA, France, India, and China. For further information, visit: www.pace.com.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.

No Offer or Solicitation
This document is provided for informational purposes only and does not constitute an offer to sell, or an invitation to subscribe for, purchase or exchange, any securities or the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance, exchange or transfer of the securities referred to in this document in any jurisdiction in contravention of applicable law.

Forward-Looking Statements
This document may contain forward-looking statements concerning certain trends, expectations, forecasts, estimates, or other forward-looking information affecting or relating to PACE or ARRIS or its industry, products or activities that are intended to qualify for the protections afforded “forward-looking statements” under the Private Securities Litigation Reform Act of 1995 and other laws and regulations. Forward-looking statements speak only as to the date of the document and may be identified by the use of forward-looking terms such as “may”, “will”, “expects”, “believes”, “anticipates”, “plans”, “estimates”, “projects”, “targets”, “forecasts”, “outlook”, “impact”, “potential”, “confidence”, “improve”, “optimistic”, “deliver”, “comfortable”, “trend” and “seeks,”, or the negative of such terms or other variations on such terms or comparable terminology. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, the possibility that a possible combination will not be completed, failure to obtain necessary regulatory approvals or required financing or to satisfy any of the other conditions to the possible combination, adverse effects on the market price of ARRIS shares and on ARRIS’s or Pace’s operating results because of a failure to complete the possible combination, failure to realize the expected benefits of the possible combination, negative effects relating to the announcement of the possible combination or any further announcements relating to the possible combination or the consummation of the possible combination on the market price of ARRIS shares or Pace shares, significant transaction costs and/or unknown liabilities, customer reaction to the announcement of the combination, possible litigation relating to the combination or the public disclosure thereof, general economic and business conditions that affect the combined companies following the consummation of the possible combination, changes in global, political, economic, business, competitive, market and regulatory forces, future exchange and interest rates, changes in tax laws or their interpretation or application, regulations, rates and policies, future business combinations or disposals and competitive developments. These factors are not intended to be an all-encompassing list of risks and uncertainties. Additional information regarding these and other factors can be found in ARRIS’s reports filed with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2014. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. The factors described in the context of such forward-looking statements in this Announcement could cause ARRIS’s plans with respect to Pace, ARRIS’s or Pace’s actual results, performance or achievements, industry results and developments to differ materially from those expressed in or implied by such forward-looking statements. Although it is believed that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct and persons reading this document are therefore cautioned not to place undue reliance on these forward-looking statements which speak only as at the date of this document. ARRIS and Pace expressly disclaim any obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

Important Additional Information Regarding the Transaction Will Be Filed With The SEC
It is expected that the shares of New ARRIS to be issued by New ARRIS to Pace shareholders under the scheme will be issued in reliance upon the exemption from the registration requirements of the Securities Act of 1933, as amended, provided by Section 3(a)(10) thereof. In connection with the issuance of New ARRIS shares to ARRIS stockholders pursuant to the merger that forms a part of the combination, New ARRIS will file with the SEC a registration statement on Form S-4 that will contain a prospectus of New ARRIS as well as a proxy statement of ARRIS relating to the merger that forms a part of the combination, which we refer to together as the Form S-4/Proxy Statement.

INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE FORM S-4/PROXY STATEMENT, AND OTHER DOCUMENTS FILED WITH THE SEC IN CONNECTION WITH THE TRANSACTION CAREFULLY AND IN THEIR ENTIRETY, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE TRANSACTION, THE PARTIES TO THE TRANSACTION AND THE RISKS ASSOCIATED WITH THE TRANSACTION. Those documents, if and when filed, as well as ARRIS’s and New ARRIS’s other public filings with the SEC may be obtained without charge at the SEC’s website at www.sec.gov, at ARRIS’s website at http://ir.arris.com. Security holders and other interested parties will also be able to obtain, without charge, a copy of the Form S-4/Proxy Statement and other relevant documents (when available) by directing a request by mail to ARRIS Investor Relations, 3871 Lakefield Drive, Suwanee, GA 30024 or at http://ir.arris.com. Security holders may also read and copy any reports, statements and other information filed with the SEC at the SEC public reference room at 100 F Street N.E., Room 1580, Washington, D.C. 20549. Please call the SEC at (800) 732-0330 or visit the SEC’s website for further information on its public reference room.

Participants in the Solicitation
ARRIS, its directors and certain of its executive officers may be considered participants in the solicitation of proxies in connection with the transactions contemplated by the Proxy Statement. Information about the directors and executive officers of ARRIS is set forth in its Annual Report on Form 10-K for the year ended December 31, 2014, which was filed with the SEC on February 27, 2015, and its proxy statement for its 2015 annual meeting of shareholders, which was filed with the SEC on April 9, 2015. Other information regarding potential participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the Proxy Statement/Prospectus when it is filed.

Pace and New ARRIS are each organized under the laws of England and Wales. Some of the officers and directors of Pace and New ARRIS are residents of countries other than the United States. As a result, it may not be possible to sue Pace, New ARRIS or such persons in a non-US court for violations of US securities laws. It may be difficult to compel Pace, New ARRIS and their respective affiliates to subject themselves to the jurisdiction and judgment of a US court or for investors to enforce against them the judgments of US courts.

Responsibility
The directors of ARRIS accept responsibility for the information contained in this document and, to the best of their knowledge and belief (having taken all reasonable care to ensure that such is the case), the information contained in this document is in accordance with the facts and it does not omit anything likely to affect the import of such information.

ARRIS and the ARRIS Logo are trademarks or registered trademarks of ARRIS Enterprises, Inc.  All other trademarks are the property of their respective owners. © ARRIS Enterprises, Inc. 2015.  All rights reserved.

(CAMBU) Announces Amendment of Its Merger Agreement With Parakou Tankers

(INVT) Strengthens Its Financial Management and Investor Relations (IR) Processes

(MYL), (PRGO) Board Unanimously Rejects Unsolicited Proposal

This is an announcement falling under Rule 2.4 of Irish Takeover Panel Act, 1997, Takeover Rules, 2013 (the “Irish Takeover Rules”). Proposal Substantially Undervalues Perrigo and is Not in the Best Interests of Shareholders Perrigo has Proven Track Record of Value Creation, Generating Returns of over 970% since Fiscal 2007 Perrigo’s Organic Net Sales Three-Year CAGR Goal for 2014 – 2017 is 5-10%

DUBLIN, April 21, 2015  — Perrigo Company plc (“Perrigo”) (NYSE: PRGO; TASE) today announced that its Board of Directors has unanimously rejected the unsolicited Proposal (the “Proposal”) from Mylan NV (“Mylan”) (NASDAQ: MYL), disclosed April 8, 2015, to acquire all of the outstanding shares of Perrigo for $205.00 per share. Following a thorough review, advised by its financial and legal advisors, the Board unanimously concluded that the Proposal substantially undervalues the Company and its future growth prospects and is not in the best interests of Perrigo’s shareholders.

Key factors informing the Board’s determination include:

• The Proposal substantially undervalues Perrigo’s differentiated global business, including the Company’s leading market position in key franchises, global distribution platform, and proven expertise in product development and supply chain management;
• The Proposal would deny Perrigo shareholders the full benefits of Perrigo’s durable competitive position and compelling growth strategy, which is reflected in the Company’s three-year organic net sales compound annual growth rate (CAGR) goal for calendar 2014 to 2017 of 5-10%;
• The Proposal does not take into account the full benefits of the Omega Pharma acquisition, which closed on March 30, 2015, including additional value to be derived from synergies and increased global presence; and
• The Proposal does not take into account Perrigo’s innovative new product pipeline, which is expected to generate nearly $1 billion in net sales over the next three years, excluding sizable upside from potential new indications for Tysabri®.

Joseph C. Papa, Chairman, President and CEO, said, “The Board believes the Proposal substantially undervalues Perrigo and its growth prospects and that continued execution by the management team against our global growth strategy will deliver superior shareholder value. Perrigo has a long history of driving above market shareholder value through consistent growth with a focus on profitability and operational excellence, which is reflected in our organic net sales CAGR goal of 5-10% for the next three years.  With the acquisition of Omega Pharma, we are a top five global OTC company with a diversified portfolio, a leading market position in key franchises and a strong and established global distribution platform. We will continue to capitalize on our durable competitive position by expanding our international platform organically and through future synergistic deals.  These actions will advance our leadership in the global OTC marketplace.”

Mr. Papa continued, “Perrigo’s Board believes that the Company has a strong independent future and is well positioned to continue to drive superior growth and shareholder value and provide high ‘Quality Affordable Healthcare Products®’ to customers and consumers globally.  The Board’s confidence is built upon the Company’s durable competitive position, compelling growth strategy, and strong and consistent track record of delivering results for shareholders under its experienced management team. Since fiscal 2007, we have delivered compound annual sales growth of 16%, increased adjusted operating margin by over 1,600 basis points and generated total shareholder returns of over 970%.”

Perrigo has today separately announced results for the third quarter of fiscal 2015 ending March 28, 2015 and has provided guidance for calendar year 2015 in connection with its upcoming move to a calendar fiscal year.  In the quarter, Perrigo generated record revenue, adjusted net income and operating cash flow. In addition, Perrigo’s three-year organic net sales CAGR goal from 2014 to 2017 is 5-10%.

Shareholders are strongly advised to take no action in relation to the Proposal.  There can be no certainty that any firm offer will be made, nor any certainty as to the terms on which any firm offer might be made by Mylan.

Morgan Stanley & Co.  LLC acting through its affiliate, Morgan Stanley & Co. International plc is acting as financial advisor and Wachtell, Lipton, Rosen & Katz and A&L Goodbody are acting as legal advisors to Perrigo.

Conference Call:

Perrigo will host a conference call and live webcast on Tuesday, April 21, 2015 at 5:00 p.m. (ET) to discuss the Proposal. Interested parties can access the webcast in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 877-248-9413, International 973-582-2737, and reference ID#31717586. A taped replay of the call will be available beginning at approximately 8:30 p.m. (ET) on April 21, 2015 until midnight on May 7, 2015. To listen to the replay, dial 855-859-2056, International 404-537-3406, and use access code 31717586.

Sources of Information and Bases of Calculation

The Perrigo historical sales growth and operating margin figures are derived from Perrigo’s audited financial statements.

The relevant bases of calculation and sources of information are set out below and provided in the order in which the information appears in the announcement. Where such information is repeated in the announcement the underlying sources and bases are not repeated.

The Perrigo forecasts and goals included in this announcement are derived from Perrigo’s long-range plans (LRP) and documents produced to support the long-range planning process.

The forecast for product category and new product sales forecasts and goals in this announcement are consistent with the LRP for the periods presented, which is at constant exchange rates, and reflects net sales for each category in the LRP as launching in the periods presented.  The forecasted new product launch sales included in the LRP are risk-adjusted to reflect Perrigo’s assessment of the individual probability of launch of products in development and, when applicable, timing of regulatory approval. Perrigo estimates market share penetration and pricing relative to the national brand based on historical or similar product category experience.

Information relative to interest expense and shares outstanding are based on the current capital structure at the time the forecast is made.

The total shareholder return figures included in this announcement are sourced from third party publicly available information.

Irish Takeover Rules

The directors of Perrigo accept responsibility for the information contained in this announcement. To the best of the knowledge and belief of the directors of Perrigo or Mylan (who have taken all reasonable care to ensure such is the case), the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.

A person interested in 1% or more of any class of relevant securities of Perrigo may have disclosure obligations under Rule 8.3 of the Irish Takeover Rules.

A disclosure table, giving details of the companies in whose “relevant securities” “dealings” should be disclosed can be found on the Irish Takeover Panel’s website at www.irishtakeoverpanel.ie. “Interests in securities” arise, in summary, when a person has long economic exposure, whether conditional or absolute, to changes in the price of securities. In particular, a person will be treated as having an “interest” by virtue of the ownership or control of securities, or by virtue of any option in respect of, or derivative referenced to, securities. Terms in quotation marks are defined in the Irish Takeover Rules, which can be found on the Irish Takeover Panel’s website.

If you are in any doubt as to whether you are required to disclose a “dealing” under Rule 8, please consult the Irish Takeover Panel’s website at www.irishtakeoverpanel.ie or contact the Irish Takeover Panel on telephone number +353 1 678 9020; fax number +353 1 678 9289.

[The adjusted EPS guidance for calendar year 2015 provided by Perrigo in its third quarter results announcement constitutes a profit forecast for the purposes of the Irish Takeover Rules.  This profit forecast will be reported on by Perrigo’s reporting accountants and financial advisors in accordance with Rule 28.3 of the Irish Takeover Rules at the relevant time.  Other than the reference to the aforementioned guidance provided by Perrigo for calendar year 2015, nothing in this announcement is intended to be a profit forecast or asset valuation and no statement in this announcement, other than aforementioned profit forecast, should be interpreted to mean that the earnings per Perrigo share for the current or future financial periods will necessarily be greater than those for the relevant preceding financial period.]

Non-GAAP Statements

This press release includes certain historical non-GAAP financial measures.  The reconciliation of those measures to the most comparable GAAP measures is included at the end of this press release.

Non-GAAP guidance for calendar 2015 excludes amortization of intangibles, restructuring and unusual litigation charges, along with transaction and financing costs related to the Omega acquisition.  At this time, a reconciliation to GAAP earnings per share guidance for calendar 2015 is not available without unreasonable effort.  The Company expects that the unavailable reconciling items, which primarily include the amortization of intangibles and non-cash charges related to Omega, along with other expenses not related to our core operations, which may be related to the integration of Omega, the Company’s change in fiscal year and a recent indication of interest for the acquisition of the Company, could significantly impact its financial results.

Important Information

Morgan Stanley & Co.  LLC acting through its affiliate, Morgan Stanley & Co. International plc, is financial advisor to Perrigo and no one else in connection with the matters referred to in this announcement. In connection with such matters, Morgan Stanley & Co.  LLC, Morgan Stanley & Co. International plc, each of their affiliates and each of their and their affiliates’ respective directors, officers, employees and agents will not regard any other person as their client, nor will they be responsible to any other person other than Perrigo for providing the protections afforded to their clients or for providing advice in connection with the contents of this announcement or any other matter referred to herein.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company’s future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential” or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company’s control, including future actions that may be taken by Mylan in furtherance of its unsolicited proposal.  These and other important factors, including those discussed under “Risk Factors” in the Perrigo Company’s Form 10-K for the year ended June 28, 2014, as well as the Company’s subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

About Perrigo

Perrigo Company plc, a top five global over-the-counter (OTC) consumer goods and pharmaceutical company, offers consumers and customers high quality products at affordable prices. From its beginnings in 1887 as a packager of generic home remedies, Perrigo, headquartered in Ireland, has grown to become the world’s largest manufacturer of OTC products and supplier of infant formulas for the store brand market. The Company is also a leading provider of generic extended topical prescription products and receives royalties from Multiple Sclerosis drug Tysabri®. Perrigo provides “Quality Affordable Healthcare Products®” across a wide variety of product categories and geographies primarily in North America, Europe, and Australia, as well as other key markets including Israel and China.

A copy of this announcement will be available on Perrigo’s website at www.perrigo.com.

Appendix

(VICL) To Present Preclinical Data for Congenital CMV DNA Vaccine at International Conference

• A Vaxfectin^®-formulated gB DNA vaccine induces antibodies that block cytomegalovirus entry into fibroblasts and epithelial cells in preclinical study
• Data presented at the 5^th International Congenital CMV Conference in Brisbane, Australia

SAN DIEGO, April 21, 2015  — Vical Incorporated (Nasdaq:VICL) today announced that Michael McVoy, Ph.D., Professor of Pediatrics at Virginia Commonwealth University, presented data from preclinical studies testing several combinations of Vaxfectin^®– formulated glycoprotein-B (gB)-encoding DNA vaccines for neutralizing antibody responses. The data were featured at the 5^th International Congenital CMV Conference held April 20-24, 2015, in Brisbane, Australia. Vaxfectin is Vical’s novel, proprietary cationic lipid-based adjuvant and is used in CyMVectin^™, the company’s congenital CMV vaccine candidate. The studies found that vaccines encoding gB provided both fibroblast and epithelial entry neutralizing titers that were comparable to those observed in sera from humans with naturally-acquired CMV infections. The data suggest that CyMVectin has the potential to induce neutralizing antibodies against a broad range of cells.

“A vaccine to prevent birth defects caused by cytomegalovirus is a public health priority,” said Dr. Stuart Adler, M.D., Emeritus Professor, Department of Microbiology and Immunology, at Virginia Commonwealth University. “Accumulating evidence suggests that induction of antibodies that block viral entry into a broad range of cell types is an important determinant of vaccine efficacy. A gB DNA vaccine performs well in this regard, when compared with responses induced by natural infection. In addition, the simplicity of a single subunit delivered by DNA immunization is highly attractive compared with more complicated vaccines in development.”

“We believe that induction of both fibroblast and epithelial entry neutralizing antibodies is essential for providing protection against CMV,” said Larry Smith, PhD., Vical’s Vice President of Vaccine Research. “These findings support further development of CyMVectin for prevention of congenital CMV infections.”

About Congenital CMV

Currently, in the United States, approximately 40,000 children are born with a congenital CMV infection each year. Of these, about 4,000 have symptoms at birth and will have severe sequelae including deafness, mental impairment, and/or death. According to the National Cytomegalovirus Registry for Pregnant Women, congenital infection of a fetus usually occurs when a woman’s first CMV infection occurs during pregnancy. In the United States approximately 60% of pregnant women are seronegative and between 1% and 2% will have a primary CMV infection during pregnancy. The rate of CMV transmission to the fetus after a primary maternal infection during pregnancy is between 25% and 75% depending on gestational time of infection.

About Vical

Vical develops biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases, based on its patented DNA delivery technologies and other therapeutic approaches. Additional information on Vical is available at www.vical.com.

Forward-Looking Statements

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include the potential benefits of CyMVectin and potential future development of CyMVectin. Risks and uncertainties include whether Vical or others will continue development of CyMVectin, whether planned clinical development of CyMVectin will begin when expected, or at all, whether the results of future preclinical or clinical studies will be consistent with prior preclinical studies or will otherwise merit further development; whether Vical will seek or gain approval to market any product candidates, including CyMVectin; and additional risks set forth in the company’s filings with the Securities and Exchange Commission. These forward-looking statements represent the company’s judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

CONTACT: Andrew Hopkins
         (858) 646-1127
         Website: www.vical.com

(FTNT) Gets Best Positioning in Latest NSS Labs Real-World Testing

Fortinet’s NGIPS Receives NSS Labs Coveted ‘Recommended’ Rating, Scoring Top Marks in Security, Performance and TCO Against Competitors

(AST) Phase 2 Clinical Data on Telomerase-based Dendritic Cell Cancer Vaccine AST-VAC1

MENLO PARK, Calif., April 21, 2015  — Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that the abstract describing long-term follow-up of patients with acute myelogenous leukemia (AML) from the Phase 2 clinical trial of the Company’s autologous  telomerase-based dendritic cell cancer vaccine, AST-VAC1, has been selected for an oral presentation at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held in Chicago, Illinois May 29 – June 2, 2015.

The abstract accepted for oral presentation is titled, “Long-term follow-up of patients with acute myelogenous leukemia receiving an autologous telomerase-based dendritic cell vaccine.” The data will be presented by H. Jean Khoury, MD, FACP, professor of hematology and medical oncology, and director of the Division of Hematology in the Department of Hematology and Medical Oncology at Emory University School of Medicine during the session titled, “Leukemia, Myelodysplasia, and Transplantation” and is scheduled for Saturday, May 30, 2015 from 3:09 PM to 3:19 PM Central time. The abstract number is 7007.

“We are honored that the ASCO Scientific Program Committee has selected our Phase 2 study in patients with AML for oral presentation, which is typically reserved for important clinical and translational research findings,” said Pedro Lichtinger, President and CEO of Asterias. “We are looking forward to Dr. Khoury’s presentation in this prestigious scientific forum, and to discussing the long-term follow-up data with key opinion leaders in the oncology community during the ASCO meeting.”

About AST-VAC1

AST-VAC1 is an autologous product (using cells that come from the treated patient) consisting of mature antigen-presenting dendritic cells pulsed with RNA for the protein component of human telomerase (“hTERT”) and a portion of a lysosomal targeting signal (“LAMP”). LAMP directs the telomerase RNA to the lysosome, the subcellular organelle that directs the RNA to a particular part of the cell membrane. AST-VAC1 is injected into the patient’s skin; and from there the dendritic cells travel to the lymph nodes and instruct cytotoxic T-cells (T-cells that “kill” other cells) to kill tumor cells that express telomerase on their surface.

About Asterias Biotherapeutics

Asterias Biotherapeutics, Inc. (NYSE MKT: AST) is a leading biotechnology company in the emerging field of regenerative medicine. The Company’s core technologies center on pluripotent stem cells, which are characterized by the ability to become all cell types in the human body. Asterias is focused on developing therapies based on pluripotent stem cells to treat diseases or serious injuries in several medical areas where there is high unmet medical need and without adequate available therapies. Asterias’ two therapeutic programs, AST-OPC1 (oligodendrocyte progenitor cells) for spinal cord injuries and AST-VAC2 (antigen-presenting allogeneic dendritic cells) for lung cancer, are based on the Company’s proprietary technology platforms of Pluripotent Stem Cells and Allogeneic Dendritic Cell Immunotherapy, respectively. AST-OPC1 is currently in a Phase 1/2a clinical trial. Additional information about Asterias can be found at www.asteriasbiotherapeutics.com.

FORWARD-LOOKING STATEMENTS

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Asterias, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the businesses of Asterias, particularly those mentioned in the cautionary statements found in Asterias’ filings with the Securities and Exchange Commission. Asterias disclaims any intent or obligation to update these forward-looking statements.

(ECHO) to Acquire Command Transportation

Acquiring Highly Complementary Business of Command Transportation to Create Industry Leading Third Party Logistics and Multimodal Transportation Services Provider; Transaction to Increase Scale and Add Density to National Footprint, Positioning Echo Global Logistics to Better Serve the Truckload Brokerage Market; $420 Million Purchase Price for Command Transportation, Which Had $561 Million in 2014 Revenue

(ENG) Board Approves Stock Repurchase Program

HOUSTON, April 21, 2015  — ENGlobal (Nasdaq:ENG), a leading provider of engineering and automation services, today announced that its Board of Directors has authorized the repurchase of up to $2 million of the Company’s Common Stock.

Shares may be repurchased through open market or privately negotiated transactions, based on prevailing market conditions. The buyback program will be executed with internally generated corporate funds and the shares acquired will be retired and returned to the status of authorized but unissued.

About ENGlobal

ENGlobal (Nasdaq:ENG) is a provider of engineering and related project services primarily to the energy sector throughout the United States and internationally. ENGlobal operates through two business segments: Automation and Engineering. ENGlobal’s Automation segment provides services related to the design, fabrication and implementation of advanced automation, control, instrumentation and process analytical systems. The Engineering segment provides consulting services for the development, management and execution of projects requiring professional engineering, construction management, and related support services. Within the Engineering segment, ENGlobal’s Government Services group provides engineering, design, installation and operation and maintenance of various government, public sector and international facilities, and specializes in the turnkey installation and maintenance of automation and instrumentation systems for the U.S. Defense industry worldwide. Further information about the Company and its businesses is available at www.ENGlobal.com.

Safe Harbor for Forward-Looking Statements

The statements above regarding the Company’s expectations regarding its operations and certain other matters discussed in this press release may constitute forward-looking statements within the meaning of the federal securities laws and are subject to risks and uncertainties For a discussion of additional risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see ENGlobal’s filings with the Securities and Exchange Commission, including the Company’s most recent reports on Form 10-K and 10-Q, and other SEC filings.

Click here to join our email list:http://www.b2i.us/irpass.asp?BzID=702&to=ea&s=0.

CONTACT: Mark A. Hess
         (281) 878-1040
         ir@ENGlobal.com

(KMDA) Additional Data from European Phase 2/3 Clinical Study of Inhaled Alpha-1 Antitrypsin

Kamada Ltd. (Nasdaq and TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces additional results from its European Phase 2/3 clinical trial of the Company’s inhaled alpha-1 antitrypsin (AAT) to treat AAT deficiency (AATD). Kamada performed these post hoc analyses in accordance with guidance received following the Company’s meeting with European Medicines Agency (EMA) Rapporteurs in December 2014. The goal of these analyses is to further evaluate lung function results using the most rigorous statistical methods to confirm that the efficacy signal previously identified is valid and robust.

Lung Function Results

Results from the post hoc analyses indicate that after one year of daily inhalation of Kamada’s AAT, clinically and statistically significant improvements were seen in spirometric measures of lung function, particularly in bronchial airflow measurements FEV₁ (L), FEV₁% predicted and FEV₁/SVC. These favorable results were even more evident when analyzing the overall treatment effect throughout the full year.

For lung function, overall one year effect:

• FEV₁ (L) rose significantly in AAT treated patients and decreased in placebo treated patients (+15ml for AAT vs. -27ml for placebo, a 42 ml difference, p=0.0268)
• There was a trend towards better FEV₁% predicted (0.54% for AAT vs. -0.62% for placebo, a 1.16% difference, p=0.065)
• FEV₁/SVC% rose significantly in AAT treated patients and decreased in placebo treated patients (0.62% for AAT vs. -0.87% for placebo, a 1.49% difference, p=0.0074)

For lung function change at week 50 vs. baseline:

• There was a trend towards reduced FEV₁ (L) decline (-12ml for AAT vs. -62ml for placebo, a 50 ml difference, p=0.0956)
• There was a trend towards a reduced decline in FEV1% predicted (-0.1323% for AAT vs. -1.6205% for placebo, a 1.4882% difference, p=0.1032)
• FEV₁/SVC% rose significantly in AAT treated patients and decreased in placebo treated patients (0.61% for AAT vs. -1.07% for placebo, a 1.68% difference, p=0.013)

“Based on the encouraging and important lung function outcomes of the trial, we are proceeding with our plan to submit the Marketing Authorization Application (MAA) to the EMA within the coming year for Conditional Approval of our inhaled AAT to treat AAT Deficient patients. The EMA has agreed to evaluate these post hoc analyses from this innovative study,” stated David Tsur, Co-founder and CEO of Kamada. “The clinical strategy of the file will be based on primary analyses of lung functions and symptom improvements. Importantly, we believe the combination of lung functions, which are the gold standard measurements for pulmonary diseases, and symptom improvements, along with the safety profile of the product, gives us confidence that these data meet the risk/benefit balance required by EMA. We are also planning to initiate discussions this year with the U.S. Food and Drug Administration (FDA) on the regulatory pathway for registration of the product in the U.S.”

Prof. Jan Stolk, M.D., Department of Pulmonology, Leiden University Medical Center, Principal Investigator of the Phase 2/3 clinical trial and acting Chairman of the Alpha 1 International Registry (AIR), stated, “The study results demonstrated, primarily in the overall treatment effect on lung functions, are of significant clinical value. This study is the first study ever that is indicative of inhaled AAT’s ability to potentially reduce lung inflammation as expressed by its preservation of lung function and the changes shown in symptoms. As the Chairman of the Alpha 1 International Registry, I am encouraged by these results and I hope that the regulatory authorities will acknowledge the clinical significance of this study for the benefit of the AAT deficient patients in Europe, who currently in many cases are suffering from severe lung disease with an unmet medical need.”

Prof. Kenneth Chapman, M.D., Director of the Canadian Registry for the Alpha-1 Antitrypsin Deficiency (Asthma and Airway Centre in Toronto Western Hospital, University of Toronto) and an investigator in the Phase 2/3 clinical trial, commented, “These new analyses confirm the clinically-meaningful lung function improvement seen with inhaled AAT patients in this study. This is the first time that a controlled, randomized trial in AAT deficiency has demonstrated efficacy using widely accepted clinical endpoints. As we know, all currently marketed therapies were approved based on pharmacokinetic data. These results are impressive and underscore the initial findings from this study. In my opinion, inhaled AAT has shown to be an efficacious treatment for this orphan disease.”

Robert A. Sandhaus, Ph.D., M.D., FCCP, Founder and Director of the Alpha1-Antitrypsin Deficiency Program at National Jewish Health in Denver, Colorado, and the Clinical Director of the Alpha-1 Foundation, expressed enthusiasm regarding the data, stating, “The study analysis suggests exciting results that may lead to wider acceptance of the inhaled route of administration of alpha-1 antitrypsin augmentation therapy, which could be a real breakthrough for AATD patients.”

The additional results after performing analyses of the data using Mixed Model Repeated Measures method (MMRM) are presented in the table below.

Table 1: Spirometry analyses for changes at week 50 vs. baseline and for overall treatment effect in the study [MMRM method]

The MMRM method takes into consideration both fixed effects and random effects, and is useful in cases where repeated measures are taken. This method is favorably accepted among regulatory bodies, especially as it is advantageous in dealing with missing values, a frequent occurrence in orphan disease trials. In addition, the regulatory authorities recommended that Kamada apply different imputation models that in aggregate may help provide a stronger indication on the robustness of the results. This included methods known as multiple imputations, jump to reference, copy reference, missing at random and others. All analysis of the spirometric measurement of lung function using those multiple imputation methods reinforced the same directional trends as seen in the table above.

The diffusion measures in lung function didn’t show differences between groups such as DLCO % of predicted and DLCO/VA % of predicted.

The diffusion capacity (DLCO) represents the gas exchange capacity of AATD patients, which is specifically affected by the extent of damage to the alveolar parenchyma in the emphysematous tissue. The scarred emphysematous tissue is not operational and is not functioning properly in the exchange of gases. Considering its anti-protease, anti-inflammatory and anti-apoptotic properties, it is likely that a longer treatment period would be required to potentially reverse tissue damage in the middle stages of the disease processes. Kamada expects that DLCO will be one of several lung function measurements evaluated during post-marketing studies.

Dyspnea and Well-being Scores

Additional data collected throughout the trial for exacerbation symptom score and well-being score are shown in the following graphs. The changes in symptoms of dyspnea and well-being are suggested as those that most influence the change in patients’ health, and quality of life (QoL) status and determine the need for additional therapy: the lower the score, the better the patient condition (score values are between 5 to 20). The results showed trends in favor of the AAT-treated group for both dyspnea and well-being but were not statistically significant, largely due to the small sample size.

A scoring system developed by Prof. R.A. Stockley, M.D., Professor of Medicine at Birmingham University and Medical Director of the Lung Resource Centre, Queen Elizabeth Hospital, Birmingham, U.K. and a principal investigator of the European Phase 2/3 study, was used as a monitoring tool to assess exacerbations within an electronic diary that was recorded daily by the patients. This tool (Bronkotest) includes a simple grading system to determine the magnitude of exacerbation symptoms change during the trial.

Of the three symptoms that comprise the Anthonisen Exacerbation Criteria (i.e., dyspnea, sputum volume and sputum color), dyspnea is the predominant, most common and distressing symptom in Chronic Obstructive Pulmonary Disease (COPD) and AATD. It is considered to be one of the most debilitating symptoms that has a major effect on patients’ suffering,adversely affecting their quality of life. Dyspnea symptom scores were electronically captured in this study on a daily basis through the patients’ e-diaries. In addition, the diary included a score for patient well-being, which is also considered to be one of the critical indicators of patients’ disease state and their drive for treatment during development of an exacerbation.

According to Prof. Stockley, “This study has enlightened our understanding about the course of exacerbation events, specifically with respect to its composite symptoms, exacerbation severity and frequency with linkage to patients’ baseline disease. Importantly, the improvements seen in well-being and dyspnea in the inhaled AAT treated patients suggest that in addition to lung function improvements, these patients are seeing important improvement in their symptoms, which are correlated to quality of life.”

Previously Reported Data

Previous data reported by Kamada in September 2014 included:

• Exacerbations (primary and secondary endpoints of the study: Time to, Rate, Duration, Severity of the first) – No signal or significance/trend towards placebo
• Safety – No difference between groups

The improvement in dyspnea and well-being further correlates with the fact that patients inhaling AAT had better preserved airflow than patients inhaling placebo. Despite this correlation to lung function, change in exacerbation events parameters (primary and secondary endpoints) was not seen in this study, most probably as a result of a limited sample size and between-groups imbalance of other clinical parameters at baseline that affected the ability to discern changes in these exacerbation endpoints. When the study protocol was being designed, these parameters were selected as primary and secondary endpoints based on existing regulatory draft guidance and on further regulatory guidance given on several occasions. Other endpoints were considered to be less suitable given the small sample sizes available due to the orphan nature of the disease.

“Originally, this study was conducted to examine the hypothesis that AAT by inhalation may affect the duration and severity of exacerbation events in AATD patients prone to having frequent moderate-to-severe exacerbations. Having evaluated real-time data collected on disease and/or exacerbation symptoms, an important and clinically meaningful improvement in symptoms associated with the exacerbations was discovered. In particular, favorable changes observed in the two most critical parameters of dyspnea and well-being follow a similar pattern throughout the study,” noted Naveh Tov, M.D., Ph.D., Medical Director of Kamada. “The graphs shown above clearly indicate that after several weeks of treatment with inhaled AAT there is an improvement in both dyspnea and well-being in the AAT group while such an improvement is not seen in the placebo group. These changes were not statistically significant between the two groups as expected in post hoc analysis, but showed a clear and consistent trend.”

“We will present the study results in their entirety at a panel meeting led by dedicated Key Opinion Leaders during the American Thoracic Society (ATS) Annual Meeting next month in Denver, Colorado. This forum will provide an opportunity for the Company to receive further clinical feedback from different lung disease medical specialists and will be the first time during which we publicly discuss a conclusive set of results from our inhaled AAT trial. We are very excited by this opportunity and look forward to sharing the totality of these data in that forum,” commented Pnina Strauss, Vice President for Clinical Development and Intellectual Property at Kamada. “We also look forward to sharing the results from our U.S. Phase 2 study of inhaled AAT in our follow on discussions with the EMA and to reporting additional data from the open-label extension portion of this Phase 2/3 study by year end.”

About Kamada
Kamada Ltd. is focused on plasma-derived protein therapeutics for orphan indications, and has a commercial product portfolio and a robust late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived proteins. AAT is a protein derived from human plasma with known and newly-discovered therapeutic roles given its immunomodulatory, anti-inflammatory, tissue-protective and antimicrobial properties. The Company’s flagship product is Glassia®, the first and only liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. Food and Drug Administration. Kamada markets Glassia in the U.S. through a strategic partnership with Baxter International. In addition to Glassia, Kamada has a product line of nine other pharmaceutical products that are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, India and other countries in Latin America, Eastern Europe and Asia. Kamada has five late-stage plasma-derived protein products in development, including an inhaled formulation of AAT for the treatment of AAT deficiency that completed a pivotal Phase 2/3 clinical trials in Europe and has initiated Phase 2 clinical trials in the U.S. Kamada also leverages its expertise and presence in the plasma-derived protein therapeutics market by distributing 10 complementary products in Israel that are manufactured by third parties.

Cautionary Note Regarding Forward-Looking Statements
This release includes forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E of the US Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, such as statements regarding assumptions and results related to financial results forecast, commercial results, clinical trials, Intellectual Property, the EMA and U.S. FDA filings and authorizations and timing of clinical trials. Forward-looking statements are based on Kamada’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, unexpected results of clinical trials, delays or denial in the U.S. FDA or the EMA approval process, additional competition in the AATD market or further regulatory delays. The forward-looking statements made herein speak only as of the date of this announcement and Kamada undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

(ASTI) Completes New $1M Common Stock Investment Via Existing Largest Shareholder

Ascent Solar Technologies, Inc. (NASDAQ:ASTI), a developer and manufacturer of state-of-the-art, flexible thin-film photovoltaic modules integrated into the company’s EnerPlex™ series of consumer products, announced today that it entered into a Stock Purchase Agreement (SPA) on April 9, 2015 with existing stockholder TFG Radiant Investment Group (“TFG Radiant”) for $1.0 million of common stock. The transaction closed on April 17, 2015.

The transaction was priced at a fixed per share price of $1.00 and the Company has issued 1,000,000 restricted shares to TFG Radiant. The shares will become unrestricted one year from the closing date.

With this investment, TFG Radiant’s ownership in the Company has increased to approximately 17.0% of the outstanding common stock subsequent to the closing.

Dr. Amit Kumar, Chairman of Ascent Solar, stated, “TFG Radiant has been very supportive of the company, and we appreciate their continued enthusiasm and interest in Ascent. Their confidence in our current business direction underscores the future prospects for Ascent. We look forward to continuing achieving milestones in product launches, revenue growth and profitable operations.”

Winston Xu, Chairman of TFG Radiant, said, “We are more upbeat now than ever with regards to Ascent’s future success and believe this is a good time to increase our ownership stake in the company. Ascent has demonstrated growing sales momentum the last two years and the Company is clearly at an inflection point of its development where a strong foundation has been built to enable accelerating growth in sales. As the largest shareholder of Ascent Solar, TFG Radiant strongly believes in Ascent’s business plan and is firmly committed to the Company and its strategy for growth.”

About Ascent Solar Technologies, Inc.:

Ascent Solar Technologies, Inc. is a developer of thin-film photovoltaic modules with substrate materials that are more flexible, versatile and rugged than traditional solar panels. Ascent Solar modules can be directly integrated into consumer products and off-grid applications, as well as aerospace and building integrated applications. Ascent Solar is headquartered in Thornton, Colorado. For more information, go to www.goenerplex.com or www.ascentsolar.com.

Forward-Looking Statements:

Statements in this press release that are not statements of historical or current fact constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause the Company’s actual results to be materially different from any historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements that explicitly describe these risks and uncertainties, readers are urged to consider statements that contain terms such as “believe,” “expect,” “intend,” “anticipate,” “plan,” and other words and terms of similar meaning to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the SEC. The Company disclaims any intention or obligation to update or revise any financial or other projections or other forward-looking statements, whether because of new information, future events or otherwise.

(FTNT) Surveys Reveal Growing Cyber Threat Concerns

Third-Party Research Reveals Consumer Behavior May Present Greater Challenges for Enterprises That Do Not Have the Right Security Protections in Place

(GENE) Additional Breast Health Centres to Begin Offering BREVAGenplus(R)

(IKGH) Junket Operator MOU With Crown Perth Casino & Crown Melbourne Casino

Iao Kun Group Holding Company Limited (“IKGH”) (NASDAQ:IKGH), which operates through its subsidiaries and related promotion entities that act as VIP room gaming promoters and a collaborator, today announced that it has entered into a non-binding memorandum of understanding whereby it will acquire all of the profit interests of Mr. Lou Kan Kuong (the “Seller”) for acting as a junket operator for the Crown Perth Casino in Perth, Australia and for the Crown Melbourne Casino in Melbourne, Australia. The Seller, who is currently an officer of IKGH, recently entered into agreements to act as a junket operator for the Casinos on behalf of IKGH. IKGH expects to close the transaction by mid-May 2015 and to begin generating initial revenues under this agreement shortly thereafter.

IKGH is purchasing the interests for nominal value.

“We are excited to take this first step toward expanding our operations and presence internationally and beginning to diversify our sources of revenue,” said IKGH Chairman Lam. “We are pleased to have the opportunity to establish ourselves in Australia and work with both the Crown Perth Casino and Crown Melbourne Casino to bring our VIP clients to their first-class facilities. Further, we remain committed to finding additional opportunities to expand our presence overseas and ultimately generating long-term value for our shareholders.”

About Iao Kun Group Holding Company Limited

IKGH is a holding company which operates through its subsidiaries and related promotion entities that act as VIP room gaming promoters and a collaborator, and is entitled to receive all of the profits of the VIP gaming promoters and collaborator from VIP gaming rooms. IKGH’s VIP room gaming promoters and collaborator currently participate in the promotion of five major luxury VIP gaming facilities in Macau, China, the largest gaming market in the world. One VIP gaming room is located at the top-tier 5-star hotel, the StarWorld Hotel & Casino in downtown Macau, and another is located in the luxury 5-star hotel, the Galaxy Macau™ Resort in Cotai, each of which is operated by Galaxy Casino, S.A. Additional VIP gaming rooms are located at the Sands Cotai Central and City of Dreams Macau, both in Cotai, and Le Royal Arc Casino, located in NAPE, Downtown Macau.

Forward-Looking Statements

This press release includes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements, based upon the current beliefs and expectations of IKGH’s management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The gaming industry is characterized by an element of chance. Theoretical win rates for IKGH’s promotion entities’ VIP gaming room operations depend on a variety of factors, some beyond their control. In addition to the element of chance, theoretical win rates are also affected by other factors, including gaming patrons’ skill and experience, the mix of games played, the financial resources of gaming patrons, the spread of table limits, the volume of bets placed by IKGH’s promotion entities’ gaming patrons and the amount of time gaming patrons spend on gambling — thus VIP gaming rooms’ actual win rates may differ greatly over short time periods, such as from quarter to quarter, and could cause their quarterly results to be volatile. These factors, alone or in combination, have the potential to negatively impact the VIP gaming rooms’ win rates. Investors and potential investors should consult all of the information set forth herein and should also refer to the risk factors set forth in IKGH’s Annual Report on Form 20-F filed in April 2015, and other reports filed or to be filed from time-to-time with the Securities and Exchange Commission.

Iao Kun Group Holding Company Limited
James Preissler, 646-450-8808
preissj@ikghcl.com

(WPCS) Stockholders Overwhelmingly Approve Authorization for Reverse Stock Split Proposal

1-for-22 Split Filed to Address May 4, 2015 NASDAQ Compliance Deadline

(MNTA) Announces FDA Approval of ANDA for Glatopa(TM)

• First generic multiple sclerosis product approved in the United States
• Approval triggers $10 million milestone payment to Momenta

CAMBRIDGE, Mass., April 16, 2015  — Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), today announced that the U.S. Food and Drug Administration has granted marketing approval of Sandoz’s Abbreviated New Drug Application for once daily Glatopa™ (glatiramer acetate injection, formerly M356) 20 mg/mL, a generic equivalent of daily COPAXONE^® 20 mg. Glatopa is the first substitutable generic indicated for the treatment of patients with relapsing-forms of multiple sclerosis (RRMS), a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. Glatopa was developed under a collaboration agreement between Momenta and Sandoz and is the second complex generic developed by Momenta together with Sandoz to receive FDA approval. Glatopa will be commercialized under the Sandoz brand.

“We are proud to be able to offer patients with multiple sclerosis the first generic version of daily COPAXONE and the first generic product in this space,” said Craig Wheeler, President and CEO, Momenta Pharmaceuticals. “The FDA approval of the ANDA for once daily Glatopa further validates Momenta’s approach of using innovative physicochemical and biologic characterization to gain approval of complex generics, biosimilars and novel drugs, and advances Momenta’s goal of expanding access to high quality, more affordable medicines.”

Glatopa was determined by the FDA to be therapeutically equivalent to daily COPAXONE 20 mg, with the same active ingredients, route of administration, strength and dosage form. Glatopa’s high quality U.S.-based supply chain and manufacturing process meets rigid FDA standards, and Glatopa is fully substitutable at the pharmacy level. Glatopa is expected to offer a more affordable treatment option for people living with RRMS.

Under the terms of its collaboration agreement with Sandoz, Momenta is eligible to receive up to $140 million in milestone payments upon the achievement of certain U.S. regulatory, commercial and sales-based milestones for Glatopa, including a $10.0 million payment earned upon sole FDA approval of the ANDA, and another $10.0 million milestone payment upon first commercial sale.

Sandoz is currently evaluating launch timing.

Momenta will host a conference call and webcast for investors today at 1:30 p.m. ET to discuss the approval of this important generic medicine. Conference call and webcast details will follow in a separate press release.

Conference Call Information

Momenta will host a conference call for investors on April 16, 2015 at 1:30 p.m. ET to provide more information about the Glatopa approval. The conference call will be webcast live and a link to the webcast may be accessed on the “Investors” section of the company’s website, www.momentapharma.com. Please go to the site at least 15 minutes prior to the call to register, download, and install any necessary software. An archived version of the webcast will be posted on the Momenta website approximately two hours after the call.

About Relapsing-Remitting Multiple Sclerosis (RRMS)

Multiple sclerosis is a devastating chronic disease of the central nervous system characterized by inflammation and neurodegeneration. RRMS, defined by inflammatory attacks on the protective coating of neurons (myelin) and characterized by intermittent bouts of symptoms, is the most common disease course at the time of diagnosis. COPAXONE is among the leading products marketed for treatment of RRMS. It works by stopping the body from damaging its own nerve cells (myelin). In North America, COPAXONE is marketed by Teva Neuroscience, Inc., which is a subsidiary of Teva Pharmaceuticals.

About Momenta

Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for oncology and autoimmune indications.

To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release. The company’s logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.

Forward Looking Statements

Statements in this press release regarding management’s future expectations, beliefs, intentions, goals, strategies, plans or prospects, including statements relating to its beliefs and intentions related to Glatopa, including those about distribution and commercialization, pricing, potential sales or revenue, the achievement of milestones and receipt of associated payments under the Company’s collaboration with Sandoz, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may contain such words as “anticipate,” “believe,” “could,” “could increase the likelihood,” “hope,” “target,” “project,” “goals,” “potential,” “predict,” “might,” “estimate,” “expect,” “intend,” “is planned,” “may,” “should,” “will,” “will enable,” “would be expected,” “look forward,” “may provide,” “would” or similar terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors referred to in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014 filed with the Securities and Exchange Commission under the section “Risk Factors,” as well as other documents that may be filed by Momenta from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company’s actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. Momenta is providing the information in this press release as of the date of this press release and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

COPAXONE is a registered trademark of Teva Pharmaceuticals. Glatopa is a trademark of Novartis AG.

CONTACT: Investor Relations:
         Sarah Carmody
         Momenta Pharmaceuticals
         1-617-395-5189
         IR@momentapharma.com

         Media Relations:
         Karen Sharma
         MacDougall Biomedical Communications
         1-781-235-3060
         Momenta@macbiocom.com

(PZG) Announces Completion of Spin-Off and Acquisition by Coeur Mining, Inc.

Paramount Gold and Silver Corp.
Christopher Crupi, CEO
Chris Theodossiou, Investor Relations
(866) 481 2233

(MYL) Federal Circuit Upholds U.S. Patents on Perforomist®

POTTERS BAR, England and PITTSBURGH, April 17, 2015 — Mylan N.V. (Nasdaq: MYL) today announced the United States Court of Appeals for the Federal Circuit upheld the validity and infringement of all four patents asserted by Mylan Specialty, L.P. protecting its Perforomist® (formoterol fumarate) Inhalation Solution. The Court summarily affirmed the previous decision by the district court against Teva.

Today’s decision prevents Teva from receiving final approval of its ANDA from the U.S. Food and Drug Administration (FDA) prior to expiration of U.S. Patent Nos. 6,667,344; 6,814,953; 7,348,362; and 7,462,645. Those patents cover Perforomist^® until they expire in June 2021.

Mylan CEO Heather Bresch commented: “The court’s decision today again recognizes the validity of the patents covering Mylan’s Perforomist^® Inhalation Solution, reaffirming the strength of our intellectual property on this product. We are excited about the growth of our respiratory franchise and look forward to continuing to meet unmet needs in this increasingly important space.”

This press release includes statements that constitute “forward-looking statements,” including with regard to the outcome of legal proceedings, product approvals, sales of products, future operations, anticipated business levels, future earnings, planned activities, anticipated growth, market opportunities, strategies, and competition. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: any legal or regulatory challenges to the appellate decision; risks inherent in legal and regulatory processes; the ability to protect intellectual property and preserve intellectual property rights; impacts of competition; uncertainties and matters beyond the control of management, and the other risks detailed in the company’s filings with the Securities and Exchange Commission. The company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what’s right, not what’s easy; and impact the future through passionate global leadership. We offer a growing portfolio of around 1,400 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in about 145 countries and territories. Our workforce of approximately 30,000 people is dedicated to creating better health for a better world, one person at a time. Learn more at mylan.com

(CSPI) Launches New Unified Brand Image, Website and Architecture

Reflects New Corporate Image and Growth Strategy

BILLERICA, Mass., April 15, 2015  — CSP Inc. (Nasdaq:CSPI), a provider of IT solutions and high-performance Ethernet products for diverse applications, today announced that it has created a new, unified brand architecture that better reflects the Company’s image and growth strategy.

CSPi’s new branding initiative follows a move last year by the Company to rename its reporting segments to more clearly reflect the operating businesses in each segment and its unified growth strategy. A key element of CSPi’s new growth strategy is to drive sales by focusing on cross selling within and between its segments. Under the new branding architecture, the Company’s segments include “CSPi High Performance Products,” which offers multicomputer products and offerings from the Myricom business (now under the unified CSPi brand as “Myricom, Products by CSPi”) as well as “CSPi Technology Solutions,” which includes all of the formerly branded Modcomp businesses, which now have been unified under the CSPi brand.

“CSPi has made significant strategic moves with its acquisitions, has established two distinct business divisions, and developed a more singular mindset in its operations,” said President and Chief Executive Officer Victor Dellovo. “Refreshing and repositioning the CSPi brand is a natural next step in our Company’s growth and success. The new unified brand architecture supports our overall Company and our growth initiatives.”

CSPi’s new brand image is a more modern, clean and sophisticated image that depicts technology as the Company’s core focus. The rebranding initiative represents the next step in CSPi’s evolution and is an architecture that the Company can grow into as it continues to expand its businesses. The Company also launched a new website at www.cspi.com that is a reflection of the new branding and architecture.

About CSPi

CSPi (Nasdaq:CSPI) maintains two distinct and dynamic divisions – High Performance Products and Technology Solutions – with a shared vision for technology excellence. CSPi’s High Performance Products division offers extreme-performance Ethernet products for diverse applications, including cybersecurity, financial trading, content creation/distribution, storage networking applications, as well computer signal processing systems. CSPi’s Technology Solutions division provides innovative technology solutions for network solutions, wireless & mobility, unified communications & collaboration, data center solutions, advanced security, along with professional and managed services across those technology focus areas. CSPi Technology Solutions works with the world’s leading IT software and infrastructure companies to create solutions for the unique IT requirements of its customers. For more information, please visit www.cspi.com

Safe Harbor  

The Company wishes to take advantage of the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995 with respect to statements that may be deemed to be forward-looking under the Act. Such forward-looking statements may include, but are not limited to, those related to future growth and expansion. The Company cautions that numerous factors could cause actual results to differ materially from forward-looking statements made by the Company. Such risks include general economic conditions, market factors, competitive factors and pricing pressures, and others described in the Company’s filings with the SEC. Please refer to the section on forward-looking statements included in the Company’s filings with the Securities and Exchange Commission.

CONTACT: Michele Merrell
         Vice President, Global Marketing & Communications, CSPi
         (954) 571.4622
         michele.merrell@cspi.com

(TROV) Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study

Non-invasive liquid biopsy enables detection of emerging T790M mutations with greater sensitivity than tissue biopsy and months before detection of cancer progression with imaging Tracking circulating tumor DNA (ctDNA) in urine enables determination of response to novel EGFR T790M inhibitors within days of initial treatment Oral presentation selected for Best Abstracts session at the 2015 European Lung Cancer Conference

SAN DIEGO, April 17, 2015  — Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, announced today that clinical data presented at the 2015 European Lung Cancer Conference (ELCC) demonstrate that its urine-based Precision Cancer Monitoring^℠ (PCM) platform outperformed tissue biopsy for the detection and monitoring of EGFR T790M mutations in metastatic lung cancer patients. The abstract, titled Detection of EGFR T790M Mutation in Urinary Circulating Tumor DNA from Metastatic Non-Small Cell Lung Cancer Patients, was presented today by Hatim Husain, M.D., University of California, San Diego Moores Cancer Center during the ESMO-IASLC Best Abstracts session in Geneva, Switzerland.

In an interim analysis of 34 patients from an ongoing clinical study, Trovagene’s PCM platform detected the T790M mutation in all patients who were positive for the mutation in tissue biopsy. The Company’s urine-based assay identified additional patients as T790M-positive, including those who had clinical suspicion of T790M-progressive disease, but were either negative by tissue biopsy or had not yet undergone tissue biopsy for confirmation. Trovagene’s PCM platform detected EGFR T790M resistance mutations months earlier than radiologic detection of progression in patients.

Early pharmacodynamic events occurring within hours or days of anti-EGFR drug treatment were evaluated in the study by implementing daily monitoring of urinary ctDNA. Initial results demonstrated that immediate changes in EGFR mutational load using a urine specimen may identify patients who respond to anti-EGFR therapy much earlier than with follow-up CT-scans. This new clinical utility of urinary ctDNA is being further validated in a larger patient cohort.

“These interim results suggest that use of urinary ctDNA has potential to detect EGFR T790M status in a higher number of study subjects and may make some patients eligible for therapy who would by tissue biopsy be falsely classified as negative,” stated Dr. Husain. “Detecting the emergence of EGFR T790M mutations before progression has the potential to enable physicians to better align therapeutic selection and inform early therapeutic decision making.”

Added Antonius Schuh, PhD, chief executive officer of Trovagene, “These compelling data using a completely non-invasive specimen support the potential of our PCM platform to transform the way clinicians monitor and treat lung cancer patients. Last year, we showed that we could detect and monitor the BRAF V600E mutation in histiocytic disease and change the way clinicians diagnose and treat Erdheim-Chester disease. Today we are following the same course in lung cancer by identifying more patients with driver mutations, observing the immediate effects of targeted therapy, and tracking a key resistance mutation. We continue to add to the body of clinical evidence supporting our proprietary liquid biopsy platform for cancer monitoring, and remain focused on improving the standard of cancer care.”

About The T790M Mutation in Non-Small Cell Lung Cancer

While lung cancer is one of the most aggressive malignancies, progress has been made in the advancement of therapeutic strategies against the disease. In particular, epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, in non–small cell lung cancer (NSCLC) patients with EGFR mutations have demonstrated clinical response rates as high as 80%. However, after about 6 to 12 months, most tumors develop acquired resistance to these targeted therapies. Research into such resistance has identified the secondary T790M mutation, which occurs in approximately 60% of patients with acquired resistance to EGFR-TKIs and is reported to negate the benefits of treatment. To date, no effective treatment options have been approved for NSCLC patients with the T790M mutation, however new targeted drug candidates such as rociletinib and AZD9291 are in advanced clinical development, and have shown promise for this indication.

European Lung Cancer Conference – 15 – 18 Apr 2015

The European Society for Medical Oncology (ESMO) and The International Association for the Study of Lung Cancer (IASLC) recently announced that the European Lung Cancer Conference (ELCC), will become an annual meeting as of 2015. ELCC will encourage cooperation with the most important societies representing thoracic oncology specialists, forming a truly multidisciplinary team and reinforcing the science, education and practice of lung cancer treatment across Europe and beyond.

About Trovagene, Inc.

Headquartered in San Diego, California, Trovagene is leveraging its proprietary technology for the detection and monitoring of cell-free DNA in urine.  The Company’s technology detects and quantitates oncogene mutations in cancer patients for improved disease management. Trovagene’s Precision Cancer Monitoring^SM platform is designed to provide important clinical information beyond the current standard of care, and is protected by significant intellectual property including multiple issued patents and pending patent applications globally.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend,” among others. These forward-looking statements are based on Trovagene’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or fourth party payer reimbursement; limited sales and marketing efforts and dependence upon fourth parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement.  Investors should read the risk factors set forth in Trovagene’s Form 10-K for the year ended December 31, 2014 and other periodic reports filed with the Securities and Exchange Commission.

Trovagene Contacts

(XPLR) Agrees to Purchase Motion Computing

Xplore Technologies Corp. (NASDAQ: XPLR) (“Xplore” or the “Company”), a manufacturer of award-winning rugged tablet PCs, announced today that it has agreed to acquire substantially all of the assets of Motion Computing, Inc. and its subsidiaries (“Motion”). Motion, another Austin, TX-based leader in the rugged tablet space, is currently the #2 provider worldwide of rugged tablet PCs, according to VDC.

“The acquisition of Motion is consistent with our goal to establish the best and broadest line of rugged tablets for the enterprise market,” said Philip Sassower, chairman and CEO of Xplore. “Motion represents a unique opportunity for Xplore to acquire an Austin-based company with deep industry domain expertise and that possesses products and channels complementary to our own. Together we will address a broader range of customer needs and provide a ‘one-stop shop’ for rugged tablets.”

“Nearly fifty percent of Motion revenue comes from outside the United States,” said Mark Holleran, president and COO of Xplore. “Leveraging the mature distribution channels that Motion has developed over the last 10 years, Xplore will significantly expand its international reach. We are particularly excited to include in our offering Motion’s R12, which was recently named by PC Magazine as Editor’s Choice for Rugged Windows Tablet PC. Its 12.5” LCD form factor has been very successful in law enforcement and manufacturing markets and is just one example of the expanding market in which Xplore will now participate.”

“Motion is excited about what this combination brings to its customers and business partners,” said Peter Poulin, CEO of Motion. “The capital backing of Xplore supports a robust product pipeline and customer service capabilities that are critical to enterprises with whom Motion has had long standing relationships.”

“Xplore has a proven track record in focusing its resources to generate sustainable growth,” said Mike Rapisand, CFO of Xplore. “After a successful recapitalization and offering in 2012, we invested cash to significantly expand our addressable market, revenue and EBITDA. Our executive management team has over 200 years’ combined experience in managing companies like Xplore and Motion, and we are confident that the two business will be successfully integrated to deliver growth and value to all of our stakeholders.”

The transaction will be effected through an asset purchase and sale agreement by and among Xplore, Motion and Square 1 Bank. Xplore will acquire Motion for approximately $9 million, plus the assumption of approximately $7 million in net liabilities. The closing of the transaction is expected to occur on or about April 17, 2015 and is subject to numerous conditions, including the receipt of financing and third party approvals and the satisfaction of customary closing conditions. Xplore intends to consummate the transaction using proceeds from a new $15 million credit facility with Square 1 Bank and to support integration and growth of the two businesses with its cash on hand.

In its most recent fiscal year ended December 31, 2014, Motion’s unaudited revenue was approximately $83 million, its unaudited gross margin percentage was approximately 25% and its unaudited net loss was approximately $7 million. Xplore intends to file a current report on Form 8-K on or about June 30, 2015 that will include Motion financial statements, as well as historical pro forma financial information for the combined businesses.

The Company will conduct a conference call at 4:30 pm EST on Thursday, April 16, 2015, to provide additional information on this transaction. Interested parties in the United States can access the call by dialing 877-269-7756; interested parties outside the United States can access the call by dialing 201-689-7817; a live webcast is available at http://www.investorcalendar.com/IC/CEPage.asp?ID=173821; and a replay of the conference call will be available until May 15, 2015, by calling 877-660-6853 from the United States or 201-612-7415 from outside the United States and entering conference ID number 13606316.

About Xplore Technologies®

Xplore Technologies Corp. has been a leading global provider of truly rugged tablets since 1996. Xplore tablets are among the most powerful and longest lasting in their class, withstand nearly any hazardous condition or environmental extreme, and feature competitive pricing and significant ROI. The company’s products are sold on a global basis, with channel partners in the United States, Canada, Europe and Asia Pacific. Xplore Technologies’ tablets are deployed across a variety of industries and sectors, such as energy, military operations, manufacturing, distribution, public services, public safety, government, and other areas with hazardous work conditions. For more information, visit the Xplore Technologies website at www.xploretech.com.

About Motion

Motion Computing® empowers organizations worldwide with technology solutions designed to optimize the performance of mobile workers. Building on a foundation of award-winning technical expertise and decades of industry experience, the Motion® team makes it their business to understand your business. Through industry-leading rugged tablet PCs, tailored accessories and services – Motion delivers mobile technology solutions customized to business workflows. Purposely built for vertical markets including field service, healthcare, utilities, construction, retail, public safety and first responders – Motion’s suite of mobile technology solutions improves worker productivity, data accuracy and security, while enabling real-time decision making at the point-of-service. Customers report lower operational expenses, increased efficiency and enhanced customer service. Motion makes its solutions available through a global network of value added resellers and distributors.

Forward Looking Statements

This news release contains forward-looking statements that involve risks and uncertainties, which may cause actual results to differ materially from the statements made. When used in this document, the words “may”, “would”, “could”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” and similar expressions are intended to identify forward-looking statements. Such statements reflect Xplore’s current views with respect to future events and are subject to such risks and uncertainties. Many factors could cause actual results to differ materially from the statements made including those factors detailed from time to time in filings made by Xplore with securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated or expected. Xplore does not intend and does not assume any obligation to update these forward-looking statements.

Taglich Brothers
Chris Schreiber, 917-445-6207
cs@taglichbrothers.com

(CLRX) and Medytox Solutions Sign Definitive Merger Agreement

Combination Will Create New Generation Healthcare Company

SAN FRANCISCO and WEST PALM BEACH, Fla., April 16, 2015  — CollabRx, Inc. (Nasdaq:CLRX) (“CollabRx”) and Medytox Solutions, Inc. (OTCQB: MMMS) (“Medytox”) today announced that they have entered into a definitive merger agreement. Closing of the merger is subject to, among other things, gaining stockholder approvals from both companies, receipt of regulatory approvals and other customary closing conditions.

Under the terms of the agreement, which has been unanimously approved and adopted by the Boards of Directors of both CollabRx and Medytox, CollabRx equityholders will own a 10% stake in the combined company and Medytox equityholders will own 90% of the combined company, based on the number of equity securities outstanding immediately following the merger, and excluding convertible preferred shares and notes issued by Medytox, as well as option grants expected to be made in connection with the closing.

Medytox currently owns and operates a diverse family of healthcare companies, including several clinical testing laboratories, an electronic medical records provider, a laboratory information systems company and a medical billing company. CollabRx is a leading informatics company focused on the interpretation of complex molecular and genetic tests in cancer.

For the twelve months ending December 31, 2014, Medytox Solutions reported net revenue of $57.9 million and income from operations of $15.7 million, an increase of 38.3% and 8.0%, respectively, over the same twelve-month period in 2013. For the same twelve-month period, CollabRx reported revenues of $415,000, with net losses of ($4.3 million).

“We expect that this merger will dramatically speed up our growth,” said Seamus Lagan, CEO of Medytox Solutions, Inc. “Furthermore, the addition of CollabRx adds great depth to our company and places Medytox among the most elite, most innovative healthcare enterprises operating in the industry today. Together, we will show the world how state-of-the-art technology and vertical integration can improve health outcomes, and return value to shareholders in the process.”

Thomas Mika, CEO of CollabRx, said: “I cannot be more enthusiastic about this outcome for all CollabRx stakeholders, including our shareholders, customers, team members and advisors. CollabRx will continue its mission to better inform decision-making in cancer within a high-growth, profit-oriented company, while being able to support several exciting Medytox initiatives in precision medicine.”

Following the merger, Seamus Lagan will be CEO of the combined company. Thomas Mika and Dr. Paul Billings will be appointed to the combined company’s seven-member board, which will include the five current directors of Medytox. Mr. Mika will serve as Executive Chairman, as well as CEO of CollabRx, Inc., which will operate as a wholly-owned subsidiary of the combined companies.

Aegis Capital Corp served as exclusive financial advisor for CollabRx, Inc. and Goodwin Procter, LLP acted as legal advisor.

Akerman LLP acted as legal advisor to Medytox Solutions, Inc.

Participants in Solicitation

CollabRx (Nasdaq:CLRX), Medytox (OTCQB: MMMS), and their respective directors, executive officers, and other employees may be deemed to be participants in the solicitation of proxies from CollabRx and Medytox stockholders with respect to the proposed business combination. Information about CollabRx’s directors and executive officers is available in CollabRx’s proxy statement for its 2014 annual meeting of stockholders, dated July 28, 2014. Information about Medytox’s directors and executive officers is available in Medytox’s annual report on Form 10−K for the year ended December 31, 2013. Additional information about the interests of potential participants will be included in the registration statement and joint proxy statement and other materials filed with the Securities and Exchange Commission (the “SEC”). These documents are available free of charge at the SEC’s website at www.sec.gov, or by going to CollabRx’s Investors page on our corporate website at www.collabrx.com or by going to Medytox’s Investors page on its corporate website at www.medytoxsolutionsinc.com.

Additional Information

This document does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. CollabRx will file a registration statement, including a joint proxy statement of CollabRx and Medytox and a prospectus of CollabRx, and other materials with the SEC in connection with the proposed business combination. We urge investors to read these documents when they become available because they will contain important information. Investors will be able to obtain free copies of the registration statement and proxy statement, as well as other filed documents containing information about CollabRx and Medytox, at www.sec.gov, the SEC’s website or by going to CollabRx’s Investors page on our corporate website at www.collabrx.com or by going to Medytox’s Investors page on its corporate website at www.medytoxsolutionsinc.com.

About CollabRx, Inc.

CollabRx, Inc. (Nasdaq:CLRX) is a recognized leader in cloud-based expert systems to inform healthcare decision-making. CollabRx uses information technology to aggregate and contextualize the world’s knowledge on genomics-based medicine with specific insights from the nation’s top cancer experts, starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care. More information may be obtained at http://www.collabrx.com.

About Medytox Solutions, Inc.

Medytox Solutions Inc. (OTCQB: MMMS) is a holding company that owns and operates businesses in the medical services sector. Medytox is a new generation healthcare enterprise that delivers a single source for integrated solutions. Medytox applies its innovative approach through an outstanding suite of IT & software solutions, revenue cycle management and financial services, combined with a range of diagnostic testing and other ancillary services for the healthcare sector. Its principal line of business is clinical laboratory blood and urine testing services, with a particular emphasis in the provision of urine drug toxicology testing to physicians, clinics and rehabilitation facilities in the United States. More information may be obtained at http://www.medytoxsolutionsinc.com.

CollabRx, Inc. Safe Harbor Statement

This press release includes forward-looking statements about CollabRx’s anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and CollabRx’s plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by CollabRx with the Securities and Exchange Commission. CollabRx undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances. The potential business combination referenced in this press release is subject to, among other things, stockholder approvals and other customary conditions.  We cannot assure you that the contemplated business combination will be consummated.

Medytox Solutions, Inc. Safe Harbor Statement

This press release contains certain forward-looking information about Medytox Solutions, Inc. that is intended to be covered by the safe harbor for “forward-looking statements” provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Words such as “guidance”, “expect”, “will”, “may”, “anticipate”, “plan”, “estimate”, “project”, “intend”, “should”, “can”, “likely”, “could”, and similar expressions are intended to identify forward looking statements. These statements include statements about our plans, strategies and prospects. Forward-looking statements are not guarantees of performance. These statements are based upon the current beliefs and expectations of our management and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot assure you that the expectations will prove to be correct. Important factors that could cause our actual results or performance to differ materially from the forward-looking statements include those set forth in the “Risk Factors” section of our most recent annual report on Form 10-K and in our other filings with the Securities and Exchange Commission, which filings are available on www.sec.gov. You should not place undue reliance on these forward-looking statements, which speak only as of the date such statements are made. Except to the extent required by applicable law or regulation, we undertake no obligation to update or publish revised forward-looking statements to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events. The potential business combination referenced in this press release is subject to, among other things, stockholder approvals and other customary conditions.  We cannot assure you that the contemplated business combination will be consummated.

CONTACT: CollabRx Contacts:

         Thomas R. Mika
         President & CEO
         CollabRx, Inc.
         415-248-5350

         Dian Griesel Int'l.
         Laura Radocaj - Media
         lradocaj@dgicomm.com
         212-825-3210

         Cheryl Schneider - Investors
         cschneider@dgicomm.com
         212-825-3210

         Medytox Solutions Contacts:

         Seamus Lagan
         CEO
         Medytox Solutions, Inc.
         561-855-1626

         Sebastien Sainsbury
         Director, Investor Relations
         Medytox Solutions, Inc.
         561-666-9818
         ssainsbury@medytoxsolutionsinc.com

         Marilys Caraballo - Media
         mcaraballo@weinbachgroup.com
         305-668-0070